LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Grade 3-4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study.

    Guezour, Nadia / Soussi, Ghassen / Brosseau, Solenn / Abbar, Baptiste / Naltet, Charles / Vauchier, Charles / Poté, Nicolas / Hachon, Lorry / Namour, Céline / Khalil, Antoine / Trédaniel, Jean / Zalcman, Gérard / Gounant, Valérie

    Cancers

    2022  Volume 14, Issue 16

    Abstract: Background: Immune checkpoint inhibitors (ICIs) have been a major advance in treating non-small-cell lung cancer (NSCLC). Programmed cell death protein-1/programmed death-ligand 1 blockade enhances immune function, mediating anti-tumor activity, yet ... ...

    Abstract Background: Immune checkpoint inhibitors (ICIs) have been a major advance in treating non-small-cell lung cancer (NSCLC). Programmed cell death protein-1/programmed death-ligand 1 blockade enhances immune function, mediating anti-tumor activity, yet causing immune-related adverse events (irAEs). We investigated the prognostic role of Grade 3−4 irAEs on overall survival (OS). Methods: This observational study recruited advanced NSCLC patients who received ICIs at Bichat-Claude Bernard University Hospital and in a community hospital, Saint-Joseph Foundation (Paris), between 1 January 2016 and 31 December 2019. Immunotherapy as a single-agent or double-drug combination was applied in the first and later lines. Univariable and multivariable analyses were instrumental in evaluating the prognostic impact of irAEs. Results: Overall, 201 consecutive ICI-treated patients were enrolled. High-grade irAEs (Grades 3−4) occurred in 36 patients (17.9%), including 11 (30.5%) cases of pneumonitis, 8 (22.2%) of colitis, 4 (11.1%) hepatic, 3 (8.3%) dermatological, 2 (5.5%) neurological events, and 2 cases (5.5%) of poly-arthralgia. The median OS was 10.4 ± 1.36 months (95% CI:7.7−13.1), being significantly higher in patients with high-grade irAEs than those without, 27.8 months vs. 8.1 months, respectively (HR = 2.5; p < 0.0001). Multivariable analysis revealed an independent association between high-grade irAEs and longer OS (HR = 0.29, 95% CI: 0.2−0.6, p < 0.0001). Conclusions: Our real-life study confirms that high-grade irAEs predict longer OS in advanced NSCLC.
    Language English
    Publishing date 2022-08-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14163878
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.

    Gounant, Valérie / Ferré, Valentine Marie / Soussi, Ghassen / Charpentier, Charlotte / Flament, Héloïse / Fidouh, Nadhira / Collin, Gilles / Namour, Céline / Assoun, Sandra / Bizot, Alexandra / Brouk, Zohra / Vicaut, Eric / Teixeira, Luis / Descamps, Diane / Zalcman, Gérard

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2021  Volume 17, Issue 2, Page(s) 239–251

    Abstract: Introduction: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration ... ...

    Abstract Introduction: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer.
    Methods: SARS-CoV-2-spike antibodies were measured using the Abbot Architect SARS-CoV-2 immunoglobulin G immunoassay before the first injection of BNT162b2 mRNA vaccine, at week 4, and 2 to 16 weeks after the second vaccine dose administration. The factors associated with antibody response were analyzed.
    Results: Overall, 306 patients, with a median age of 67.0 years (interquartile range: 58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After a 6.7-month median follow-up, eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of the 269 serologic results available beyond day 14 after the second vaccine dose administration, 17 patients (6.3%) were still negative (<50 arbitrary units/mL, whereas 34 (11%) were less than 300 arbitrary units/mL (12.5th percentile). In multivariate analysis, only age (p < 0.01) and long-term corticosteroid treatment (p = 0.01) were significantly associated with a lack of immunization. A total of 30 patients received a third vaccine dose, with only three patients showing persistently negative serology thereafter, whereas the others exhibited clear seroconversion.
    Conclusions: SARS-CoV2 vaccines were found to be efficient in patients with thoracic cancer, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in an 88% immunization rate.
    MeSH term(s) Aged ; BNT162 Vaccine ; COVID-19 ; COVID-19 Vaccines ; Humans ; Lung Neoplasms ; Prospective Studies ; RNA, Viral ; SARS-CoV-2 ; Vaccines, Synthetic ; mRNA Vaccines
    Chemical Substances COVID-19 Vaccines ; RNA, Viral ; Vaccines, Synthetic ; mRNA Vaccines ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2021-11-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2021.10.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.

    Assoun, Sandra / Theou-Anton, Nathalie / Nguenang, Marina / Cazes, Aurélie / Danel, Claire / Abbar, Baptiste / Pluvy, Johan / Gounant, Valérie / Khalil, Antoine / Namour, Céline / Brosseau, Solenn / Zalcman, Gérard

    Lung cancer (Amsterdam, Netherlands)

    2019  Volume 132, Page(s) 65–71

    Abstract: Introduction: Tumor mutational burden (TMB) correlates with response to immune checkpoint inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that TP53 mutations could reflect TMB and be associated with ICI benefit.: ... ...

    Abstract Introduction: Tumor mutational burden (TMB) correlates with response to immune checkpoint inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that TP53 mutations could reflect TMB and be associated with ICI benefit.
    Methods: TP53 mutations were assessed by next-generation sequencing in aNSCLC patients treated with programmed death-1 (PD-1) blockers. Clinical data, tumor programmed death ligand-1 (PD-L1) expression, and KRAS mutational status were collected. The primary endpoint was overall survival (OS).
    Results: In total, 72 patients (median [interquartile range] age: 61 [33-83] years) were included; 52 (72%) were male; 39 (54%) had performance status 0-1; 53 (74%) had adenocarcinoma; 20 (28%) received first-line ICI, 52 (72%) second line or more. In 65 patients with available data, 36 (55%) expressed PD-L1 in ≥50% of tumor cells, 20 (31%) in 1-49% of cells, and nine (14%) were PD-L1-negative. Non-synonymous TP53 mutations were observed in 41 (57%) and 25 (35%) harbored KRAS-mutated tumors. After a median follow-up of 15.2 months (95% confidence interval [CI] 10.3-17.4 m), the median OS in the TP53-mutated group was 18.1 months (95% CI 6.6-not reached), vs. 8.1 months (95% CI 2.2-14.5, hazard ratio [HR] = 0.48; 95% CI 0.25-0.95, p = 0.04) in the TP53-wild-type group. Median progression-free survival was significantly longer in TP53-mutated patients (4.5 months, 95% CI 2.8-18.1 versus 1.4, 95% CI 1.1-3.5; p = 0.03), although TP53 mutation status failed to significantly influence PFS in the multivariate analysis (p = 0.32). Objective response rate (ORR) was higher in patients with TP53 mutation (51.2% vs. 20.7%; p = 0.01). In multivariate analysis, TP53 mutations independently associated with longer OS (HR = 0.35, 95% CI 0.16-0.77, p = 0.009).
    Conclusions: TP53-mutated status correlated with immunotherapy OS benefit in aNSCLC.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; Biomarkers, Tumor/genetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Female ; Follow-Up Studies ; High-Throughput Nucleotide Sequencing ; Humans ; Immunotherapy/methods ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation/genetics ; Neoplasm Staging ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/genetics ; Retrospective Studies ; Survival Analysis ; Tumor Suppressor Protein p53/genetics
    Chemical Substances Antineoplastic Agents, Immunological ; B7-H1 Antigen ; Biomarkers, Tumor ; CD274 protein, human ; KRAS protein, human ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; TP53 protein, human ; Tumor Suppressor Protein p53 ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
    Language English
    Publishing date 2019-04-08
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 632771-0
    ISSN 1872-8332 ; 0169-5002
    ISSN (online) 1872-8332
    ISSN 0169-5002
    DOI 10.1016/j.lungcan.2019.04.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2135: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 423: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses

    GOUNANT, Valerie / FERRE, Valentine Marie / SOUSSI, Ghassen / charpentier, Charlotte / FLAMENT, Heloise / FIDOUH, Nadhira / COLLIN, Gilles / NAMOUR, Celine / ASSOUN, Sandra / BIZOT, Alexandra / BROUK, Zohra / VICAUT, Eric / TEXEIRA, Luis / DESCAMPS, Diane / ZALCMAN, Gerard

    medRxiv

    Abstract: Hypothesis Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic cancer patients. Given that cancer patients were excluded from serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine registration trials, ...

    Abstract Hypothesis Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic cancer patients. Given that cancer patients were excluded from serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine registration trials, it is still unknown whether they would develop a protective anti-spike antibody response following vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to SARS-CoV2 vaccine in thoracic cancer patients. Methods SARS-CoV2-spike antibodies were measured using Abbot ARCHITECT SARS-CoV-2 IgG immunoassay, prior to first injection of BNT162b2 mRNA vaccine, as well as at Week 4, and two-to-sixteen weeks after second vaccine dose. The factors associated with antibody response were analyzed. Results Overall, 306 patients, with a median age of 67.0 years (IQR=58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After 4.7-month median follow-up, seven patients (2.3%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of 269 serological results available beyond Day 14 post-second vaccine dose, 17 (6.3%) were still negative (<50 AU/mL) (arbitrary units/mL), while 34 (11%) were <300 AU/mL (12.5th percentile). In multivariate analysis, only age and chronic corticosteroid treatment were significantly associated with a lack of immunization. Thirty patients received a third vaccine dose, with only three patients showing persistent negative serology thereafter, whereas the others demonstrated clear seroconversion. Conclusion SARS-CoV2 vaccines were shown to be efficient in thoracic cancer patients, most of them being immunized after two doses. A third shot given to 11% of patients with persistent low antibody titers resulted in a 88% immunization rate.
    Keywords covid19
    Language English
    Publishing date 2021-08-13
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.08.12.21261806
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment

    Lièvre, Astrid / Turpin, Anthony / Ray-Coquard, Isabelle / Le Malicot, Karine / Thariat, Juliette / Ahle, Guido / Neuzillet, Cindy / Paoletti, Xavier / Bouché, Olivier / Aldabbagh, Kais / Michel, Pierre / Debieuvre, Didier / Canellas, Anthony / Wislez, Marie / Laurent, Lucie / Mabro, May / Colle, Raphael / Hardy-Bessard, Anne-Claire / Mansi, Laura /
    Colomba, Emeline / Bourhis, Jean / Gorphe, Philippe / Pointreau, Yoann / Idbaih, Ahmed / Ursu, Renata / Di Stefano, Anna Luisa / Zalcman, Gérard / Aparicio, Thomas / Moulin, Solenne / Leleu, Olivier / Leparree, Sylvie / Goasdoue, Henri / Piprot, Christine / Tourneur, Gerald / Bayart, Vincent / Lignier, Delphine / Lachaier, Emma / Khamari, Marwa / Coutte, Alexandre / Siembida, Nicolas / Houessinon, Aline / Regimbeau, Jean Marc / Chauffert, Bruno / Moreira, Aurélie / Hautefeuille, Vincent / Hee, Christine / Boone, Mathieu / Bihan, Céline / Chive, Emilie / Poulet-Potriquier, Stéphane / Fahem, Rachida / Luet, Dominique / Roquin, Guillaume / Vitellius, Carole / Cornet-Trichereau, Nathanaëlle / Caroli-Bosc, François-Xavier / Thirot-Bidault, Anne / Ropert, Stanislas / Gachet - Masson, Julie / Dehais, Mélanie / L'helgoualc'h, Gwen-Ael / Ali-Mahamadou, Ibrahim / Talfi, Safia / Belmont, Laure / Kilendo, Dieudonné / Benrezzak, Nasro / Dubief, Emeline / Conroy, Guillaume / Delique, Laurence / Basso, Maud / Pons, Isabelle / Salignon, Karine / Villing, Anne-Laure / Mougenot, Emmanuelle / Porebski, Cassandra / Guiatni, Asma / Cloarec, Nicolas / Mineur, Laurent / Bouchaud, Marie / David, Céleste / Peytier, Annie / Greletty, Thomas / Audemar, Franck / Vignes, Emanuelle / Minne, Floriane / Goldzak, Guillaume / Huysman, Fabienne / Hocine, Fayçal / Lakkis, Zaher / Meynard, Guillaume / Almotlak, Hamadi / Klajer, Elodie / Sun, Xu-Shan / Wasselin, Julie / Catala, Pascale / Mazuy, Claire / Vandamme, Hélène / Prevost, Jean-Briac / Fadin, Aurélie / Basson, Laurent / Huguet, Jean-Baptiste / Dos Santos, Emmanuelle / Jany, Bérangère / Saad, Alain / Goutorbe, Frédéric / Oziol, Eric / Ramdani, Mohamed / Kadiri, Ouafae / Garbay, Delphine / Huet, Clotilde / Giroux Leprieur, Etienne / Teng, Wen / Monvoisin, Justine / Arnaud Coffin, Patrick / Roux, Sylvie / Orfeuvre, Hubert / Chagros, Mélanie / Pillon, Didier / Rassoul, Agathe / Poureau, Pierre Guillaume / Novello, Cécile / Ducray, François / Trouba, Cécile / Bastit, Vianney / Babin, Emmanuel / Leon, Vincent / Courtecuisse, Anne-Catherine / Vambre, Julie / Tack, Vincent / Desauw, Christophe / Meniai, Fatima / Peres, Christina / Esparcieux, Aurélie / Perrier, Hervé / Doux, Nathalie / Kaphan, Régis / Roques, Bertrand / Rebischung, Christine / Mille, Dominique / Fernandes, Gaëlle / Abdelli, Naceur / Jousset, Natacha / Combe, Pierre / Jonveaux, Eric / Dumont, Patrick / Kanaan, Marc / Berthelot Gras, Corinne / Panis, Valérie / Kaluzinski, Laure / Venant-Valery, Marjolène / Lam, You-Heng / Vallee, Laura / Riviere, Frédéric / Durand, Muriel / Benghadid, Dihya / Villeneuve, Emilie / Hentic Dhome, Olivia / Bounouar, Zedjiga / De Mestier, Louis / Dubois, Jacqueline / Eyriey, Magali / Moreau, Lionel / Baihas, Dib / Aldabbagh, Kaïs / Degriffolet, Dominique / Sebbagh, Virginie / Seghezzi, Jean-Christophe / Lozach-Brugirard, Marion / Mandrou, Julie / Mavier, Loubna / Hennetier, Florence / Wagner, Jean-Philippe / Carola, Elisabeth / Chandirakumaran, Karthiga / Loutski, Sandrine / Cojean-Zelek, Isabelle / Bouras, Amina / Lacour, Sandrine / Froura, Fahem / Ben Nadji, Hadjer / Cattelain, Sophie / Darloy, Franck / Jolimoy Boilleau, Geneviève / Maissiat, Cyrielle / Darut-Jouve, Ariane / Lorgis, Véronique / Charifi-Alaoui, Ikram / Ghiringhelli, François / Drouillard, Antoine / Chaix, Marie / Manfredi, Sylvain / Lepage, Côme / Gagnaire, Alice / Latournerie, Marianne / jourdan, Sofia / Perrot, Nora / folia, Mireille / Minello, Anne / Jouve, Jean-Louis / Fery, Marielle / Landau, Alain / Evrard, Diane / Valenza, Bruno / Paitel, Jean-François / Chablais, Laetitia / Kreitmann, Thomas / Lancry-Lecomte, Laurence / Monard, Adrien / Faugeras, Eve / Boucheret, Paul / Glommeau, Cécile / Tchikladze, Christine / Garnier Tixidre, Claire / Long, Jérôme / Zaidi, Manel / Delabarre, Véronique / Meyzenc, Juliette / Ferrand, Loïc / Moro-Sibilot, Denis / Bouheret, Paul / Leyronnas, Cécile / Herve, Camille / Thoor, Audrey / Jacquet, Emanuelle / Roth, Gaël / Madapathage-Senanyake, Videsheka / Chupeau, Peggy / Bieber, Elsa / Rosso, Maud / Lepage, Isabelle / Priou, Frank / Laly, Margot / Aprelon, Sylvie / Sobolak, Natacha / Homokos, Helen / Watelle, Fabienne / Pham-Becker, Alice / Lauridant, Géraldine / Dujardin, Charlotte / Lenglin, Etienne / Nienguet Tsota, Aimée / Dominguez, Sophie / Forestier, Alexandra / Nouvel, Franck / Lerooy, Justine / Ratajczak, Céline / Romano, Olivier / Brzyski, Dorothéee / Barriere, Aurélien / Genet, Dominique / Tisse, Julien / Zasadny, Xavier / Grelet, Adeline / Hennion-Imbault, Amélie / Haustraete, Eglantine / Louafi, Samy / Awad, Manal / Zekri, Younes / Cheneau, Caroline / Leissen, Nolwen / Egreteau, Joëlle / Breant, Alexandra / Sarabi, Matthieu / Labonne, Stéphanie / Forestier, Julien / Leclercq, Céline / Prunier-Bossion, Florence / Ray Coquard, Isabelle / Guillet, Marielle / Theillaumas, Aurélie / Prome, Emilie / Walter, Thomas / Philouze, Pierre / Lawo, Melody / De Talhouet, Solène / Beuvelot, Johanne / Molin, Yann / Bellecoste Martin, Marie / Saussereau, Maud / Agnelli, Lauren / Fakhry, Nicolas / Laplace, Christophe / Norguet Monnereau, Emmanuelle / Boucard, Céline / Djenad, Kahina / Fontaine, Catherine / Seitz, Jean-François / Dahan, Laétitia / Sigrand, Julie / Duluc, Muriel / Locher, Christophe / Fleury, Marjory / Brou Marie, Ange / Berkane, Ramdane / Poupblanc, Séverine / Auby, Dominique / Petran, Daniela / Texereau, Patrick / Guerineau, Elodie / Andre, Morgan / Mahjoubi, Linda / Sarrazin, Fanny / Jeanson, Sonia / Gschwend, Anthony / Birr, Virginie / Fore, Mathieu / Noirclerc, Monique / Dahou, Sihem / Spaeth, Dominique / Lambotin, Mélanie / Lelu, Thomas / Linot, Benjamin / Hugon, Nathalie / Rousseau, Dominique / Castanie, Hélène / Lenne, Carole / Lortholary, Alain / Cessot, Anatole / Merzoug, Messaouda / Naudin, Cécile / Vannetzel, Jean-Michel / Aziz, Ghina / Hadj Arab, Yacine / Pernes, Stéphanie / Roche-Lachaise, Isabelle / Fiteni, Frédéric / Yahiaoui, Hadjer / Marel Lopez, Gwendoline / Oddoz, Jeanne / Peira, Fabienne / Michel, Olivier / Meunier, Jérôme / Ouahrani, Brahim / Roger, Antoine / Branco, Sonia / Nguyen, Van / Gisselbrecht, Mathilde / Hammad, Ghania / Mordant, Pierre / Stroksztejn, Magda / Pocard, Marc / Nlo Meyengue, Luc / Sacco, Emmanuelle / Simon Anne, Sophie / Fabre-Guillevin, Elizabeth / Slim, Marine / Zaanan, Aziz / Cadranel, Jacques / Pluvy, Johan / Ursu, Rénata / Geraldo, Amyrath / Lihi, Rime / Vo, Maryline / Brouk, Zohra / Colle, Raphaël / Bennamoun, Mostefa / Lacan, Fabrice / Louvet, Christophe / Mebarki, Soraya / Veyri, Marianne / Paillaud, Elena / Lucas, Christelle / Dubreuil, Olivier / Lyamani, Jamila / Agguini, Hanane / Soularue, Emilie / Jourdaine, Clément / Verillaud, Benjamin / Herzine, Hakima / Raymond, Eric / Mathiot, Nathalie / Palmieri, Lola Jade / Epanya, Christian / Taieb, Julien / Bertrand, Eliane / Goujon, Gaël / Namour, Céline / Gazeau, Benoit / Zafirova, Biljana / Mirghani, Haitham / Belin, Catherine / Belkhir, Kahina / Gharib, Myriam / Vozy, Aurore / Amrane, Karim / Spano, Jean-Philippe / Wassermann, Johanna / Feuvret, Loic / Bachet, Jean-Baptiste / Philonenko, Sara / Guillot, Laetitia / Zabbe, Marion / Gibiat, Stéphanie / Baylot, Camille / Jouinot, Aude / Leduc, Nicolas / Vieillot, Sabine / James, Laurie / Ducerf, Camille / Blanc, Jean-Frédéric / Falandry Leger, Claire / Wautot, Virginie / Chauvenet, Marion / Vincent, Aude / Tougeron, David / Goulvent, Sandrine / Suc, Etienne / Laurenty, Anne-Pascale / Marquis, Eric / Bonnaire, Margaux / Dewolf, Maxime / Brenet, Esteban / Billard, Delphine / Litre, Claude-Fabien / Dumazet, Antoine / Botsen, Damien / Vazel, Marion / Carlier, Claire / Bonnerave, David / Marchand-Crety, Charles / Bouche, Olivier / Fosse, Patricia / Sefrioui, David / Watson, Sarah / Torche, Fatah / Muron, Thierry / Natur, Stéphane / Desgrippes, Romain / Bihel, Véronique / Ferrand, François-Régis / Leiterer, Caroline / Lavole, Julie / Moquet, Claire / Pressoir, Nathalie / Dziukala, Catherine / Ligeza Poisson, Catherine / Naji, Abdelhalim / Williet, Nicolas / Phelip, Jean-Marc / Di Palma, Fabrice / Kherrour Mehdi, Amina / Langrand-Escure, Julien / Fournel, Pierre / Pigne, Grégoire / Saban-Roche, Léa / Magne, Nicolas / Vassal, Cécile / Jacquin, Jean-Philippe / Ramirez, Carole / Vallard, Alexis / Collard, Olivier / Rivoirard, Romain / Graber, Ivan / Trager Maury, Stéphanie / Duboisset, Elodie / Ayllon Ugarte, Jorge / Rami, Dalilia / Saler, Christine / Reinbolt, Manon / Le Fevre, Clara / Ben Abdelghani, Meher / Dourthe, Louis-Marie / Perruisseau-Carrier, Joffrey / Nguimpi-Tambou, Marlène / Barret, Flavie / Di Stefano Anna, Luisa / Balthazard, Annie / Vassord-Dang, Camille / Le Marchand, Mathilde / Vergniol, Julien / Pripon, Iulia / Daemaegdt, Axelle / Latry, Vanessa / Larrieu, Muna / Landry, Gaëlle / Touihri Maximin, Laetitia / Del Piano, Francesco / Barlet, Agnès / Vernisse, Mylène / Lafond, Sophie / Genin, Charline / Sibertin-Blanc, Camille / Chabrillac, Emilien / Gregoire, Caroline / Vergez, Sébastien / Panouille, Quentin / Guimbaud, Rosine / Richa, Floriane / Lebellec, Loïc / Gounin, Sophie / Buiret, Guillaume / Baudin, Marine / Hamon, Hervé / Deshorgue, Anne-Claire / Barrascout, Eduardo / Legrand, Stéphanie / Houlze, Morgane / Cambula, Linda / Lopez, Anthony / Fouquet, Guillaume / Touabi, Kahina / GermaIn, Adeline / Godbert, Benoit / Voivret, Florence / Perrin, Julie / Da Silva, Rosa / Bernichon, Emilie

    European Journal of Cancer

    A French nationwide cohort study (GCO-002 CACOVID-19)

    2020  Volume 141, Page(s) 62–81

    Keywords Cancer Research ; Oncology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2020.09.035
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top